KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)

Recursion Pharmaceuticals' Asset Writedowns and Impairment history spans 4 years, with the latest figure at $6.0 million for Q1 2025.

  • For Q1 2025, Asset Writedowns and Impairment rose 5414.81% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, up 5414.81%, while the annual FY2025 figure was $6.0 million, 5414.81% up from the prior year.
  • Asset Writedowns and Impairment reached $6.0 million in Q1 2025 per RXRX's latest filing, up from $108000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $6.0 million in Q1 2025 to a low of $19000.0 in Q3 2023.
  • Average Asset Writedowns and Impairment over 4 years is $2.0 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Asset Writedowns and Impairment: crashed 90.76% in 2024, then skyrocketed 5414.81% in 2025.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $2.8 million in 2022, then plummeted by 99.32% to $19000.0 in 2023, then skyrocketed by 468.42% to $108000.0 in 2024, then skyrocketed by 5414.81% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Asset Writedowns and Impairment are $6.0 million (Q1 2025), $108000.0 (Q1 2024), and $19000.0 (Q3 2023).